Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054.

CAS  PubMed  PubMed Central  Google Scholar 

Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.

CAS  PubMed  PubMed Central  Google Scholar 

Conway EM, Mackman N, Warren RQ, Wolberg AS, Mosnier LO, Campbell RA, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022;22(10):639–49.

CAS  PubMed  PubMed Central  Google Scholar 

Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449–75.

CAS  PubMed  PubMed Central  Google Scholar 

Aboul-Fotouh S, Mahmoud AN, Elnahas EM, Habib MZ, Abdelraouf SM. What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms. Virol J. 2023;20(1):241.

PubMed  PubMed Central  Google Scholar 

Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–9.

PubMed  PubMed Central  Google Scholar 

Asdaq SMB, Rabbani SI, Alkahtani M, Aldohyan MM, Alabdulsalam AM, Alshammari MS, et al. A patent review on the therapeutic application of monoclonal antibodies in COVID-19. Int J Mol Sci. 2021;22(21):11953.

CAS  PubMed  PubMed Central  Google Scholar 

Quiros-Roldan E, Amadasi S, Zanella I, Degli Antoni M, Storti S, Tiecco G, et al. Monoclonal antibodies against SARS-CoV-2: current scenario and future perspectives. Pharmaceuticals (Basel). 2021;14(12):1272.

CAS  PubMed  PubMed Central  Google Scholar 

Bowsher RR, Devanarayan V. Are lessons learned in setting cut points for detection of anti-drug antibodies also useful in serology assays for robust detection of SARS-CoV-2 reactive antibodies? AAPS J. 2020;22(6):127.

CAS  PubMed  Google Scholar 

Liu M, Gan H, Liang Z, Liu L, Liu Q, Mai Y, et al. Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. Front Microbiol. 2023;14:1122868.

PubMed  PubMed Central  Google Scholar 

Yewdell JW. Antigenic drift: understanding COVID-19. Immunity. 2021;54(12):2681–7.

CAS  PubMed  PubMed Central  Google Scholar 

Heo CK, Lim WH, Yang J, Son S, Kim SJ, Kim DJ, et al. Novel S2 subunit-specific antibody with broad neutralizing activity against SARS-CoV-2 variants of concern. Front Immunol. 2023;14:1307693.

CAS  PubMed  PubMed Central  Google Scholar 

Guo L, Lin S, Chen Z, Cao Y, He B, Lu G. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Signal Transduct Target Ther. 2023;8(1):197.

CAS  PubMed  PubMed Central  Google Scholar 

Keitany GJ, Rubin BER, Garrett ME, Musa A, Tracy J, Liang Y, et al. Multimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells. Cell Chem Biol. 2023;30(11):1377-89 e8.

CAS  PubMed  PubMed Central  Google Scholar 

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–51.

CAS  PubMed  Google Scholar 

Zhou H, Dcosta BM, Landau NR, Tada T. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 variants to vaccine-elicited sera and therapeutic monoclonal antibodies. Viruses. 2022;14(6):1334.

CAS  PubMed  PubMed Central  Google Scholar 

Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63.

CAS  PubMed  Google Scholar 

Bork P. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? Proteins. 1993;17(4):363–74.

CAS  PubMed  Google Scholar 

Kobe B, Kajava AV. When protein folding is simplified to protein coiling: the continuum of solenoid protein structures. Trends Biochem Sci. 2000;25(10):509–15.

CAS  PubMed  Google Scholar 

Sedgwick SG, Smerdon SJ. The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem Sci. 1999;24(8):311–6.

CAS  PubMed  Google Scholar 

Pluckthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55:489–511.

CAS  PubMed  Google Scholar 

Caputi AP, Navarra P. Beyond antibodies: ankyrins and DARPins. From basic research to drug approval. Curr Opin Pharmacol. 2020;51:93–101.

CAS  PubMed  Google Scholar 

Noble A, Moorhouse E, Hay AL, Paudyal B, Mwangi W, Munir D, et al. Development of bovine IgG3-specific assays using a novel recombinant single-domain binding reagent. Vet Immunol Immunopathol. 2024;278:110852.

CAS  PubMed  Google Scholar 

Kamat V, Rafique A. Designing binding kinetic assay on the bio-layer interferometry (BLI) biosensor to characterize antibody-antigen interactions. Anal Biochem. 2017;536:16–31.

CAS  PubMed  Google Scholar 

Hernandez NE, Jankowski W, Frick R, Kelow SP, Lubin JH, Simhadri V, et al. Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus. Heliyon. 2023;9(4):e15032.

CAS  PubMed  PubMed Central  Google Scholar 

Lagasse HAD, Ou J, Sauna ZE, Golding B. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16(+) NK cell activation. Front Immunol. 2024;15:1341013.

CAS  PubMed  PubMed Central  Google Scholar 

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613–20.

Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017;21(2):131–43.

Dennison SM, Reichartz M, Seaton KE, Dutta S, Wille-Reece U, Hill AVS, et al. Qualified biolayer interferometry avidity measurements distinguish the heterogeneity of antibody interactions with plasmodium falciparum circumsporozoite protein antigens. J Immunol. 2018;201(4):1315–26.

CAS  PubMed  PubMed Central  Google Scholar 

Petersen RL. Strategies using bio-layer interferometry biosensor technology for vaccine research and development. Biosensors (Basel). 2017;7(4):49.

PubMed  PubMed Central  Google Scholar 

Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020;12(5):513.

CAS  PubMed  PubMed Central  Google Scholar 

Manu AA, Owusu IA, Oyawoye FO, Languon S, Barikisu IA, Tawiah-Eshun S, et al. Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays. Heliyon. 2024;10(10):e31392.

CAS  PubMed  PubMed Central  Google Scholar 

Cantoni D, Wilkie C, Bentley EM, Mayora-Neto M, Wright E, Scott S, et al. Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature. Front Immunol. 2023;14:1184362.

CAS  PubMed  PubMed Central  Google Scholar 

Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck JD, Lucas C, et al. Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 spike protein. Sci Rep. 2022;12(1):22175.

CAS  PubMed  PubMed Central  Google Scholar 

Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229–37.

CAS  PubMed  Google Scholar 

VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28(3):490–5.

CAS